AAV Serotype Comparison for LRRK2 Knockdown in PD

V2, Crosslink

🧫

AAV Serotype Comparison for LRRK2 Knockdown in PD

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-aav-sero

🧫 Experiment Protocol Validationproposed

SUMMARY

# AAV Serotype Comparison for LRRK2 Knockdown in PD ## Background and Rationale Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease (PD), with G2019S being the most prevalent pathogenic variant. LRRK2 gain-of-function mutations lead to increased kinase activity, resulting in neuronal dysfunction and degeneration. Adeno-associated virus (AAV)-mediated gene therapy represents a promising therapeutic approach, but optimal serotype selection is cri

METHODOLOGY NOTES

Phase 1 (Week 0): Prepare AAV vectors encoding LRRK2 shRNA in serotypes AAV1, AAV2, AAV5, AAV9, and AAVrh10 (1×10^12 vg/ml). Acclimate 60 male C57BL/6 mice (8-10 weeks) for one week. Phase 2 (Week 1): Perform stereotactic surgery under isoflurane anesthesia. Inject 2μl of AAV vectors bilaterally into substantia nigra (coordinates: AP -3.1mm, ML ±1.2mm, DV -4.2mm) using Hamilton syringe (n=10 per serotype). Include control group with saline injection. Phase 3 (Weeks 2-8): Monitor animals weekly for weight and general health. Perform behavioral assessments at weeks 4, 6, and 8 including rotarod performance (5 trials, 4-40 rpm acceleration) and cylinder test for forepaw asymmetry. Phase 4 (Week 8): Sacrifice animals via transcardial perfusion with 4% paraformaldehyde. Collect brain tissue for immunohistochemistry and separate cohort for biochemical analysis. Phase 5 (Weeks 9-12): Process tissue sections for tyrosine hydroxylase and LRRK2 immunostaining. Perform stereological counting of d

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.900874Z'}
summary	# AAV Serotype Comparison for LRRK2 Knockdown in PD ## Background and Rationale Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease (PD), with G2019
entities	{'genes': ['AAV'], 'diseases': ["Parkinson's Disease"]}
model_system	mouse
_schema_version	1
experiment_type	validation
primary_outcome	Identification of optimal AAV serotype achieving >70% LRRK2 knockdown in substantia nigra dopaminergic neurons with significant motor function improvement and minimal inflammatory response at 6 months
methodology_notes	Phase 1 (Week 0): Prepare AAV vectors encoding LRRK2 shRNA in serotypes AAV1, AAV2, AAV5, AAV9, and AAVrh10 (1×10^12 vg/ml). Acclimate 60 male C57BL/6 mice (8-10 weeks) for one week. Phase 2 (Week 1):
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.900879', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

671

Outgoing

638

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AAV Serotype Comparison for LRRK2 Knockdown in PD

derives from (16)

supports (132)

💬 Discussion